S
Setsuko K. Chambers
Researcher at University of Arizona
Publications - 158
Citations - 7181
Setsuko K. Chambers is an academic researcher from University of Arizona. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 45, co-authored 153 publications receiving 6016 citations. Previous affiliations of Setsuko K. Chambers include Yale University & University of Rochester.
Papers
More filters
Journal ArticleDOI
Uterine Papillary Serous Carcinoma Treated with Intraperitoneal Cisplatin and Intravenous Doxorubicin and Cyclophosphamide
Joseph T. Chambers,Setsuko K. Chambers,Ernest I. Kohorn,Maria Luisa Carcangiu,Peter E. Schwartz +4 more
TL;DR: This approach with intraperitoneal cisplatin presents no therapeutic advantage for patients with uterine papillary serous carcinoma and the overall survival did not differ from that of a similar group of patients treated at this institution with intravenous chemotherapy.
Journal ArticleDOI
Evaluation of the role of second-look surgery in ovarian cancer
TL;DR: The role of second-look surgery in the management of patients with ovarian cancer has come under question as mentioned in this paper, and the role of stage was a significant prognostic factor with regard to second look surgery findings, as well as absolute and disease-free survival.
Journal ArticleDOI
SGK1, a potential regulator of c-fms related breast cancer aggressiveness.
TL;DR: Serum-glucose kinase 1 (SGK1), a serine-threonine kinase known to be involved in intracellular signal transduction pathways and induced by GC and serum, is focused on to investigate additional GC-associated genetic alterations that could modulate c-fms related malignant behavior in breast cancer cells.
Journal Article
Oncogene expression in vivo by ovarian adenocarcinomas and mixed-Mullerian tumors
Barry M. Kacinski,Darryl Carter,E. I. Kohorn,Khushbakhat Mittal,R. Shaeffer Bloodgood,John Donahue,Carol Kramer,Diana B. Fischer,Rob Edwards,Setsuko K. Chambers,Joseph T. Chambers,Peter E. Schwartz +11 more
TL;DR: The authors discuss the role that tumor epithelial cell expression of the fms gene product might play in the auto- and paracrine control of growth and dissemination of ovarian adenocarcinomas.
Journal ArticleDOI
Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study
Lisa M. Hess,Helen Q. Huang,Alexandra L. Hanlon,William R. Robinson,Rhonda Johnson,Setsuko K. Chambers,Robert S. Mannel,L. E. Puls,Susan A. Davidson,Michael W. Method,Shashikant Lele,Laura J. Havrilesky,Tina Nelson,David S. Alberts +13 more
TL;DR: A subset of patients had evidence of cognitive decline from baseline during chemotherapy treatment in this study as measured by the web-based assessment; however, changes were generally limited to no more than one domain.